Related Experiment Video
Updated: Feb 24, 2026
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
Zhi Chuan Ling oral liquid alleviates Th2-type asthma via IL-4-JAK1-STAT6 and KIT signaling pathways
Jie Yang1, Xianqiang Zhou1, Ding-Zhou Weng2
1Peking University People's Hospital, Beijing, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China.
Ethnopharmacological Relevance:
Zhi Chuan Ling Oral Liquid (ZCL) has long been used in traditional Chinese medicine for the treatment of asthma. However, how ZCL acts on Th2-type asthma and its active components remain unclear.
Aim Of The Study:
This study is to investigate the mechanism and potential active substances of ZCL in intervening Th2-type asthma using an ovalbumin (OVA)-induced Th2-type asthma model.
Materials And Methods:
An OVA-sensitized and challenged Th2-type asthma mouse model was established to evaluate the effects of ZCL on airway hyperresponsiveness, Th2-type inflammatory effector cells and cytokines in bronchoalveolar lavage fluid (BALF). Proteomics was employed to identify potential targets of ZCL intervention in Th2-type asthma, and validation was performed in vitro and in vivo using molecular biology, bioinformatics, and LC-MS.
Results:
ZCL alleviated airway hyperresponsiveness and airway inflammation in Th2-type asthmatic mice, and downregulated TGF-β mRNA expression in lung tissue, decreased the numbers of eosinophils, mast cells and Th2 cytokines in BALF. Proteomic analysis suggested that ZCL may modulate Th2-type asthma via IL-4 and KIT signaling pathways. Western blotting showed that ZCL reduced the IL-4's downstream p-JAK1/JAK1 and p-STAT6/STAT6 ratios and decreased the expression of KIT and Tryptase in lung tissue. Bioinformatics analysis, LC-MS, and in vitro experiments suggest that rutin, forsythiaside, and isoforsythiaside may be the key components of ZCL responsible for intervening in the aforementioned targets.
Conclusions:
ZCL can ameliorate Th2-type asthma by suppressing IL-4 and KIT signaling pathways. Rutin, isoforsythiaside and forsythiaside are likely to be key bioactive components mediating these protective effects.
More Related Videos
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: